Sienna Biopharmaceuticals, Inc.
SNNAQ
$0.00
$0.000.00%
OTC PK
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.28% | -43.14% | -1.28% | -9.10% | 4.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.85% | -61.53% | -38.51% | 6.19% | 20.68% |
| Operating Income | 48.85% | 61.53% | 38.51% | -6.19% | -20.68% |
| Income Before Tax | 48.86% | 59.17% | 4.22% | -71.61% | -1.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 76.36% | 59.17% | 4.22% | -72.80% | -2.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.36% | 59.17% | 4.22% | -72.80% | -2.46% |
| EBIT | 48.85% | 61.53% | 38.51% | -6.19% | -20.68% |
| EBITDA | 48.94% | 61.64% | 38.60% | -6.21% | -20.64% |
| EPS Basic | 84.25% | 72.70% | 21.25% | -67.17% | 26.56% |
| Normalized Basic EPS | 64.24% | 70.56% | 42.15% | -23.45% | 23.90% |
| EPS Diluted | 84.25% | 72.70% | 21.25% | -67.17% | 26.56% |
| Normalized Diluted EPS | 64.24% | 70.56% | 42.15% | -23.45% | 23.90% |
| Average Basic Shares Outstanding | 50.08% | 49.61% | 21.64% | 3.36% | 39.52% |
| Average Diluted Shares Outstanding | 50.08% | 49.61% | 21.64% | 3.36% | 39.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |